Format

Send to

Choose Destination
ERJ Open Res. 2018 Jun 26;4(2). pii: 00028-2018. doi: 10.1183/23120541.00028-2018. eCollection 2018 Apr.

Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia.

Author information

1
Dept of Pulmonology, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, CIBERES Barcelona, Barcelona, Spain.
2
Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, NY, USA.
3
Réanimation Médicale, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
4
Thoraxzentrum Ruhrgebiet, Kliniken für Pneumologie und Infektiologie, Herne und Bochum, Germany.
5
IDIBAPS, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.
6
Dept of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
7
Pulmonary and Critical Care Division, Washington University School of Medicine, St Louis, MO, USA.
8
Dept of Medicine, Pulmonary Diseases Division, Hospital de Clínicas "José de San Martin", Universidad de Buenos Aires, Buenos Aires, Argentina.
9
Dept of Clinical Medicine, Wellcome Trust - HRB Clinical Research Facility, St. James's Hospital, Trinity College, Dublin, Ireland. CIBER de Enfermedades Respiratorias (CIBERES).
10
Emergency and Intensive Care Dept, Centro Hospitalar São João EPE, Porto, Portugal.
11
Dept of Medicine, University of Porto Medical School, Porto, Portugal.
12
NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, UK.
13
Iberoamerican Cochrane Center, Barcelona, Spain.
14
IAME, INSERM UMR 1137, Medical and Infectious Diseases Intensive Care Unit, Paris Diderot University and Bichat Hospital, Paris, France.
15
CAPNETZ STIFTUNG, Hannover, Germany.
16
Dept of Respiratory Medicine, Medizinische Hoschschule Hannover and German Center of Lung Research (DZL), Germany.
17
Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Abstract

A summary of the evidence and recommendations made in the ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia http://ow.ly/S3zA30iZfLa.

Comment in

Conflict of interest statement

Conflict of interest: A. Torres reports grants from MedImmune, Cubist, Bayer, Theravance, and from Poliphor; personal fees from Bayer (Advisory Board), Roche (Advisory Board), The Medicines CO (Advisory Board), and from Curetis (rapid molecular tests) (Advisory Board); grants as the Principal Investigator of a Phase III study of Cefatzidime/Avibactam for HAP/VAP, during the conduct of the study. He has received personal fees from GSK (Educational symposium: Siglo XXI), Pfizer (speaker at sponsored vaccine symposia), Astra Zeneca (speaker at symposia on ceftaroline), and from Biotest Advisory Board (Enriched IgM for severe CAP), outside the submitted work. Conflict of interest: M.S. Niederman reports grants and personal fees from Bayer (inhaled amikacin research grant and consulting) and Merck (nosocomial pneumonia consulting and grant), personal fees from Thermo-Fisher (procalcitonin lectures), Theravance (consulting on telavancin), and Pfizer (consulting on linezolid), during the conduct of the study. Conflict of interest: J. Chastre reports personal fees from Medimmune/AstraZeneca (honoraria for consulting), Bayer (honoraria for consulting), Pfizer (honoraria for lecture), Cubist/Merck (honoraria for data safety committee participation), Aridis (honoraria for consulting and data safety participation), and Astellas (honoraria for consulting), outside the submitted work. Conflict of interest: G. Li Bassi reports grants from Medimmune, Cubist, Covidien, Theravance, Cardeas Pharma, Ciel Medical, Biovo Technologies, and Toray, during the conduct of the study. Conflict of interest: C. Luna reports grants and personal fees from Pfizer, and personal fees from Merck Sharp and Dohne, outside the submitted work. Conflict of interest: D. Rigau is a European Respiratory Society methodologist. Conflict of interest: T. Welte reports personal fees (for lectures/advisory board) from AstraZeneca, Basilea, Bayer, Grifols, Infectopharm, Novartis and Pfizer, research grants from Bayer, Grifols, Novartis and Pfizer, research grants from the EU, German Research Council and German Ministry of Research and Education, during the conduct of the study. He has received personal fees (for lectures/advisory board) from Boehringer, Berlin Chemie, Mundipharma and Insmed, outside the submitted work. Conflict of interest: R. Wunderink reports personal fees from Arsanis, Accelerate Diagnostics, Bayer, Cepheid, GenMark, The Medicines Company, Merck, Nabriva, Polyphor and Shionogi, during the conduct of the study. Conflict of interest: M. Kollef reports personal fees from Accelerate (consultant), Merck (consultant, speaker's bureau), Paratek (consultant) and Allergan (speaker's bureau), outside the submitted work. Conflict of interest: J.F. Timsit reports research grants from Merck and 3M, a research grant to his hospital from Astelas, and educational grants from Gilead; and personal fees (for advisory boards) from Pfizer, Paratek, Merck, Bayer, 3M and Abbott, all outside the submitted work.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center